KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Accured Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Accured Expenses for 16 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 32.55% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, down 86.78% year-over-year, with the annual reading at $6.2 million for FY2025, 86.78% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $33.8 million at Halozyme Therapeutics, up from -$7.2 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $50.2 million in Q4 2024, with the low at -$29.7 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $3.3 million, with a median of -$812500.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses crashed 3007.67% in 2023, then soared 629.44% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $3.5 million in 2021, then tumbled by 90.61% to $326000.0 in 2022, then plummeted by 3007.67% to -$9.5 million in 2023, then skyrocketed by 629.44% to $50.2 million in 2024, then plummeted by 32.55% to $33.8 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $33.8 million, -$7.2 million, and -$29.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.